KFSH&RC holds the region's only ATTRv genetic registry and nuclear cardiology programme, evidence of how concentrated GCC ATTR amyloidosis expertise actually is.
GCC ATTR amyloidosis expertise concentrates around a small number of named cardiology and scintigraphy centres, not a broad regional field. KFSH&RC maintains the only GCC-wide ATTRv genetic registry and houses the region's nuclear cardiology programme, the institutional anchor for hereditary-variant identification across Saudi, UAE, and Omani kindreds. Beyond KFSH&RC, named cardiology and scintigraphy centres at KAMC, AUH, HMC Doha, and OCCI Muscat complete a field of fewer than 8 centres offering Tc-PYP scintigraphy across all six GCC states. That kind of institutional concentration does not happen by accident. Our KOL Universe gate (K1) starts by mapping exactly this structure before any single physician is scored.
That structure changes how AXLRx tiers influence across the GCC. A cardiologist based at KFSH&RC, with registry-leadership responsibility and nuclear cardiology programme access, carries different scientific weight than one working at a centre without scintigraphy or genetic-testing capability, and our Tier Classification gate (K2) scores that distinction directly, alongside institutional role and cross-border referral reach. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live institutional-affiliation and registry records, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over prescribing peers, which is exactly what the K1-K6 gate structure is built to prevent.
The GCC ATTR amyloidosis KOL structure — one registry centre, fewer than 8 named sites
| Institution | Location | Role |
|---|---|---|
| KFSH&RC | Riyadh | Only GCC-wide ATTRv genetic registry; houses the region's nuclear cardiology programme |
| KAMC | Riyadh | Named cardiology and Tc-PYP scintigraphy centre |
| AUH | Abu Dhabi | Named cardiology and Tc-PYP scintigraphy centre |
| HMC Doha | Doha | Named cardiology and Tc-PYP scintigraphy centre |
| OCCI Muscat | Muscat | Named cardiology and Tc-PYP scintigraphy centre |
Sources: GCC Cardiology Society ATTR task force 2023; KFSH&RC ATTR genetic registry; GCC ATTR case series KFSH&RC/AUH 2020-2023.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- KFSH&RC's role as the only GCC-wide ATTRv registry and nuclear cardiology programme
- named-centre concentration as a KOL-tiering signal
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- registry leadership and scintigraphy-capability weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live institutional-affiliation and registry cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against KFSH&RC's registry and nuclear cardiology role before the rest of the workbook is built out
- Every GCC ATTR amyloidosis KOL sized and sourced from institutional-affiliation and registry data
- KFSH&RC's ATTRv genetic registry and nuclear cardiology programme as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescribing cardiologist
- Scientific-influence scoring across registry leadership, scintigraphy capability, and institutional role
- What separates a Tier 1 KOL from a high-volume community cardiologist
- Influence inputs: registry authorship, nuclear cardiology programme access, institutional role
- Cross-checked against independent institutional-affiliation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across KAMC, AUH, HMC Doha, OCCI Muscat, and the wider GCC
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active beyond Saudi Arabia, across the wider GCC
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live institutional-affiliation and registry records, not secondary summaries. No KOL name ships without a verification tag.
GCC ATTR amyloidosis KOL sources: the KFSH&RC ATTRv genetic registry, GCC Cardiology Society ATTR task force records, and the named cardiology and scintigraphy centres documented in the GCC ATTR case series (KFSH&RC/AUH, 2020-2023).
- KFSH&RC's role as the only GCC-wide ATTRv registry verified against the GCC Cardiology Society ATTR task force and KFSH&RC registry records
- Named centre list (KAMC, AUH, HMC Doha, OCCI Muscat) verified against the GCC ATTR case series (KFSH&RC/AUH, 2020-2023)
- Fewer-than-8-centre regional scintigraphy count verified against the same source set
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC ATTR amyloidosis specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.